# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study.
- Reuters
Ritholtz Wealth Management's Josh Brown is putting money to work outside of tech as he anticipates money rolling into other...